Page 13 of 25: studies 241 to 260 of 481, newest first. Back to the psilocybin overview
Journal of Pre-Clinical and Clinical Research May 12, 2026 Bartłomiej Kosiarski, A. Skrzypek, Patrycja Markowicz et al.
Rapid-acting interventions in treatment-resistant depression – a comparative review of
Premier Journal of Neuroscience May 11, 2026 Khadija Kamene
Background: Treatment-resistant depression (TRD) affects a significant proportion of individuals with major depressive disorder and remains difficult to manage with conventional treatments. Psychedelic-assisted therapies and neuromodulation have emerged as innovative interventions targeting neurobiological mechanisms beyond traditional antidepressant approaches. Objectives: This scoping review...
Research Square May 11, 2026 Chloë K Walters, Sarentha Chetty, Thankhoe A Rants’o et al. preprint
Abstract Background: Conventional pharmacotherapy for treatment-resistant depression (TRD) has been found to provide limited benefit in a subset of patients. Psilocybin‑assisted therapy has emerged as a promising modality due to its rapid‑acting antidepressant effects and favourable tolerability profile shown in early trials. Despite growing research interest in psilocybin‑assisted therapy the...
International Journal of Molecular Sciences May 9, 2026 Marta Jóźwiak-Bębenista, Anna Stasiak, Monika Sienkiewicz et al.
Aging is associated with chronic, low-grade inflammation ("inflammaging"), which contributes to neuropsychiatric and neurodegenerative disorders such as depression, Alzheimer's disease, and Parkinson's disease. Conventional pharmacotherapies often provide limited benefit in older adults and are further complicated by polypharmacy and drug-drug interactions. Psilocybin, a serotonergic...
Journal of Education, Health and Sport May 7, 2026 Kinga Zachar, M. Sito, Filip Jurkowski et al.
Introduction and purpose: Depressive disorders, particularly major depressive disorder (MDD) and treatment-resistant depression (TRD), remain major causes of disability worldwide. Conventional treatments are limited by delayed onset, incomplete response, relapse, and adverse effects. This review summarizes current evidence on the efficacy, safety, and durability of psilocybin-assisted therapy...
JAMA Network Open May 7, 2026 Peter S. Hendricks, Sara N Lappan, Richard C. Shelton et al. 4 citations
Importance: Cocaine use disorder is a serious public health problem and no medications have been proven effective for its treatment. Objective: To evaluate psilocybin in the treatment of cocaine use disorder. It was hypothesized that psilocybin, compared with placebo, would yield a higher percentage of cocaine abstinent days, a greater likelihood of complete abstinence from cocaine, and a...
bioRxiv Preprint Server May 5, 2026 Povilas Tarailis, Inga Griškova-bulanova preprint
Electroencephalographic (EEG) microstates provide a compact framework for characterizing the temporal organization of large-scale brain activity, yet their sensitivity to altered brain states remains insufficiently explored. In this study, we applied broadband and frequency-resolved EEG microstate analysis to resting-state EEG data from two publicly available datasets acquired under markedly...
Nature Communications May 5, 2026 T Lyons, M Spriggs, L Kerkelä et al. 19 citations
Psychedelics have robust effects on acute brain function and long-term behavior but whether they also cause enduring functional and anatomical brain changes is largely unknown. In an exploratory, placebo-controlled, within-subjects, electroencephalography (EEG), and magnetic resonance imaging (MRI) study in 28 healthy, entirely psychedelic-naive participants, anatomical and functional brain...
American Journal of Preventive Medicine May 4, 2026 Kevin H. Yang, Nora Satybaldiyeva, Wayne Kepner et al. 1 citation
IntroductionMicrodosing involves consuming low doses of psychoactive substances, typically between 1/5th and 1/20th of a recreational dose. Despite increasing public attention to cannabis and psychedelics amid evolving drug policies, epidemiologic data on microdosing remain limited.MethodsA cross-sectional, web-based survey (Characterizing the Epidemiology of Cannabidiol Use Survey) of 1,523...
RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia May 1, 2026 Mariana Silva‐Carvalho, Andreia Machado Brito-Da-Costa, Ricardo Dinis-Oliveira et al.
Psilocybin, psilocin, 5-MeO-DMT, LSD and mescaline are classical hallucinogens whose recreational use has increased over recent decades (Brito-da-Costa et al., 2021; Dinis-Oliveira et al., 2019; Holze et al., 2021; Jiang et al., 2013). However, data on their interactions with cytochrome P450 (CYP450) enzymes remain scarce, despite the potential for clinically relevant drug–drug interactions....
RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia May 1, 2026 Andreia Machado Brito-Da-Costa, Francisco Sacadura, Ricardo Jorge Dinis-Oliveira et al.
Introduction: Psilocybin, the main psychoactive compound in Psilocybe mushrooms, has attracted interest for its potential therapeutic effects in neuropsychiatric disorders (Erkizia-Santamaría et al., 2025). However, preclinical data comparing its behavioral properties to whole mushroom extracts remain limited (Ali et al., 2023; Johnson-Groh, 2025). Objective: To investigate the reinforcing and...
RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia May 1, 2026 Andreia Machado Brito-Da-Costa, Mariana Carvalho, Ricardo Jorge Dinis-Oliveira et al.
Psilocybin is a hallucinogen produced by “magic mushrooms”, being rapidly metabolized in the organism into psilocin (Brito-da-Costa et al., 2022; Dinis-Oliveira, 2017). A scientific gap exists regarding the possible interactions between psilocybin/psilocin and CYP450 enzymes. Given their biological importance and since the binding of drugs to CYP450 enzymes can interfere with the metabolism of...
SLEEPJ May 1, 2026 Matthew J Reid, Eli Weisman, Luis Luna Martinez et al.
Despite evidence of an acute effect of psilocybin on sleep physiology, its enduring effects beyond the period of acute administration and active metabolism remain unexplored. Within a clinical trial of psilocybin-assisted therapy for alcohol use disorder comorbid with major depressive disorder, we monitored sleep for ten continuous nights (3 pre-dose | 7 post-dose) in participants (N=22)...
SLEEPJ May 1, 2026 Matthew J Reid, Abigail Yaffe, Ian Geithner et al.
Post-treatment Lyme Disease (PTLD) is a post-infectious syndrome characterized by fatigue, hypersomnia, sleep-disturbance, musculoskeletal pain and/or cognitive difficulties. As part of an open-label pilot study of psilocybin-assisted treatment for PTLD, we explored potential for psilocybin-assisted treatment to remedy sleep-related disturbances in this population. 12 participants consented to...
American Journal of Respiratory and Critical Care Medicine May 1, 2026 Louise Hecker, Jennifer Kleinhenz, Cristian Coarfa et al.
The elderly population is rapidly growing. Overwhelming epidemiologic data has demonstrated worse health outcomes with increasing age for a multitude of lung diseases (COVID being one of numerous examples). There is an increasingly urgent need for a more complete understanding of the molecular pathways and biological processes underlying aging to improve outcomes for age-associated lung...
Sleep May 1, 2026 Denise C. Vidot, Bria-Necole Diggs, Amrit Baral et al.
Abstract Introduction Psychedelic use and interest in its therapeutic potential are rapidly increasing; yet its relationship with insomnia remains poorly understood. This study aims to estimate differences in insomnia severity by type of psychedelic consumed among a cohort of 18-to-35-year olds. Methods Data are from the Herbal Heart Study - Sleep Ancillary (N=100) cannabis consumers....
Journal of Psychopharmacology May 1, 2026 Grace Viljoen, Henrik Walter, Antonia Bendau et al. 3 citations
Psychedelic-assisted therapy (PAT) has demonstrated substantial efficacy across a range of mental disorders. However, heterogeneity between patients confers differential responsiveness. This systematic review aims to explore factors which may predict therapeutic responses to PAT. A systematic search was performed from inception through to March 2024 and studies that assessed predictors of...
Molecular Psychiatry May 1, 2026 Sixtine Fleury, Katherine M. Nautiyal 4 citations
Recent studies highlight the promising use of psychedelic therapies for psychiatric disorders, including depression. The persisting clinical effects of psychedelics such as psilocybin are commonly attributed to activation of the serotonin 2A receptor (5-HT2AR) based on its role in the acute hallucinatory effects. However, the active metabolite of psilocybin binds to many serotonin receptor...
JOURNAL OF ADVANCE AND FUTURE RESEARCH May 1, 2026 Gyandev Gupta, Ravina Yadav
Depression is one of the most common mental health challenges people face today. It goes beyond just feeling sad — it shapes the way a person thinks, behaves, and experiences the world around them. The persistent low mood, the fading interest in things that once brought joy, the fog that makes even simple decisions feel overwhelming — all of it quietly chips away at a person's quality of life....
Nature Mental Health May 1, 2026 S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey et al. 2 citations
This study presents a living systematic review and open-data meta-analytic database from 15 randomized controlled trials examining the effects of psilocybin treatment on depressive symptoms. Existing evidence suggests that psilocybin treatment alleviates depressive symptoms. Depression is a major cause of disability worldwide, motivating interest in psilocybin as a potential treatment. Here we...